Convergen Raises $10 Million to Propel TrimTAC Platform for Neurodegenerative Disease Solutions Convergen has closed a $10 million seed funding round to enhance its TrimTAC platform aimed at treating neurodegenerative disorders. The funding will help tackle critical challenges in targeted protein degradation.

Convergen Raises $10 Million to Propel TrimTAC Platform for Neurodegenerative Disease Solutions #China #Suzhou #Convergen #TrimTAC #TRIM21